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By proposing TSH as a key negative regulator of bone
turnover, recent studies in TSH receptor (TSHR) null
mice challenged the established view that skeletal re-
sponses to disruption of the hypothalamic-pituitary-
thyroid axis result from altered thyroid hormone (T3)
action in bone. Importantly, this hypothesis does not
explain the increased risk of osteoporosis in Graves’
diseasepatients, inwhichcirculatingTSHR-stimulating
antibodies are pathognomonic. To determine the rela-
tive importance of T3 and TSH in bone, we compared
the skeletal phenotypes of two mouse models of con-
genital hypothyroidism in which the normal reciprocal
relationship between thyroid hormones and TSH was
intact or disrupted. Pax8 null (Pax8/) mice have a
1900-fold increase inTSHandanormal TSHR,whereas
hyt/hyt mice have a 2300-fold elevation of TSH but a
nonfunctional TSHR. We reasoned these mice must
display opposing skeletal phenotypes if TSH has ama-
jor role inbone,whereas theywouldbesimilar if thyroid
hormone actions predominate. Pax8/ and hyt/hyt
mice both displayed delayed ossification, reduced cor-
tical bone, a trabecular bone remodeling defect, and
reduced bone mineralization, thus indicating that the
skeletal abnormalities of congenital hypothyroidism
are independent of TSH. Treatment of primary osteo-
blasts and osteoclastswith TSHor a TSHR-stimulating
antibody failed to induce a cAMP response. Further-
more, TSH did not affect the differentiation or function
of osteoblasts or osteoclasts in vitro. These data indi-
cate the hypothalamic-pituitary-thyroid axis regulates
skeletal development via the actions of T3. (Molecular
Endocrinology 22: 501–512, 2008)
OSTEOPOROSIS IS A major health care priorityaffecting 50% of women and 20% of men over
50, and costing €31 billion in Europe and $14 billion in
the United States each year (1, 2). Thyrotoxicosis is an
important cause of secondary osteoporosis; uncon-
trolled hyperthyroidism accelerates skeletal remodel-
ing and increases bone loss due to uncoupling of bone
resorption and formation (3). Moreover, a history of
thyrotoxicosis is associated with an increased fracture
risk in later life (4). Although early recognition and
treatment of thyrotoxicosis means that overt bone dis-
ease is now uncommon, prospective studies have
shown a 4-fold increased fracture risk in postmeno-
pausal women with low TSH levels (5).
The detrimental effects of thyrotoxicosis have long
been attributed to actions of excess T3 on skeletal T3
receptors (TRs) (6). However, recent studies have chal-
lenged this interpretation (7). Osteoblasts and oste-
oclasts were found to express the TSH receptor
(TSHR) and respond to TSH in vitro, whereas juvenile
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TSHR null (TSHR/) mice with congenital hypothy-
roidism and treated with thyroid extract displayed high
bone turnover osteoporosis (7). These findings were
interpreted to indicate that TSH is a major and direct
inhibitor of bone turnover. Importantly, this model is
inconsistent with the increased risk of osteoporotic
fracture in Graves’ disease patients, in whom TSHR-
stimulating antibodies are pathognomonic (4).
The TSHR acts principally via adenylate cyclase to
regulate thyroid follicular cell proliferation and thyroid
hormone synthesis and release (8). Deletion of the Tshr
gene leads to congenital hypothyroidism with unde-
tectable thyroid hormone levels due to thyroid follicu-
lar hypoplasia. The lack of negative feedback on pitu-
itary thyrotrophs results in grossly elevated TSH.
TSHR/ mice display developmental delay and
growth retardation and survive beyond 4 wk only if
supplemented with thyroid extract (9). In man, con-
genital and juvenile hypothyroidism also causes
growth arrest and delayed bone maturation, whereas
thyroid hormone replacement results in rapid catch-up
growth and failure to obtain full predicted height (10,
11). Thus, high bone turnover reported in TSHR/
mice treated with thyroid extract (7) may represent
catch-up growth after treatment of juvenile
hypothyroidism.
To determine the relative importance of T3 and TSH
in bone, it is necessary to dissociate their inverse
relationship that results from negative feedback regu-
lation of TSH by thyroid hormones. We compared the
skeletal phenotypes of two mouse models of congen-
ital hypothyroidism in which this relationship was in-
tact or disrupted. Pax8 null (Pax8/) mice lack a
transcription factor essential for thyroid development
and display severe hypothyroidism with grossly ele-
vated TSH (12, 13). Hyt/hyt mice, harbor a TSHR loss-
of-function mutation also resulting in thyroid hypopla-
sia, severe hypothyroidism, and grossly elevated TSH
(14). Thus, Pax8/ mice represent a model of high
TSH with a normal TSHR, whereas hyt/hyt mice have
high TSH but a nonfunctional TSHR. If TSH has a
physiologically important role in bone, we reasoned
these mice must display opposing skeletal pheno-
types. We also investigated TSH actions in primary
osteoblasts and osteoclasts by determining TSHR ex-
pression, its effects on cell differentiation and function,
and the cellular cAMP response to TSH and TSHR-
stimulating antibodies.
RESULTS
Thyroid Status in Pax8/ and Hyt/Hyt Mice
Pax8/ mice have undetectable T4 and T3 and
1900-fold elevated levels of TSH (12, 13). Hyt/hyt
mice are also grossly hypothyroid, but their TSH
levels have not been reported. When measured in
the present study, T4 was reduced by 95% and TSH
elevated 2300-fold in hyt/hyt mice, whereas levels
were similar in wild-type (WT) mice and heterozy-
gote hyt/ (HET) mice [total T4 (mg/dl): WT 5.66 
0.80, HET 4.90  0.68, Hyt/Hyt 0.33  0.05; TSH
(mU/liter): WT 23.0  7.6, HET 36.0  8.7, Hyt/Hyt
52,856  5515; (n 3–6)].
Pax8/ and Hyt/Hyt Mice Both Have Severe
Growth Delay and Delayed Ossification
Pax8/ limbs were 19% shorter than WT littermates
at postnatal d 14 (P14) (P  0.01; n 3–5) and 8%
shorter at P70 (P  0.05; n 3–5) and exhibited de-
layed formation of secondary ossification centers (Fig.
1). Transient treatment with T3 and T4 (T3/4) before
weaning between P8 and P13 ameliorated this phe-
notype. Hyt/hyt limbs were 16% shorter than HET and
WT littermates at P49 (P  0.01; n 3–6) and dis-
played delayed formation of secondary ossification
centers. Thus, growth impairment in both Pax8/ and
hyt/hyt mice results from delayed endochondral
ossification.
Fig. 1. Growth and Skeletal Development of Pax8/ and
Hyt/Hyt Mice
A–C, Ulnas from P14 Pax8/ (A), P70 Pax8/ and T3/4-
treated (between P8 and P13) Pax8/ (B), and P49 hyt/hyt,
HET, and WT littermates (C) stained with alcian blue and
alizarin red. Arrows indicate delayed formation of secondary
epiphyses and wider growth plates in Pax8/ and hyt/hyt
mice. D, Mean lengths of tibia and ulna. *, P  0.05; **, P 
0.01 mutant vs. WT; n 3–6, 2-tailed Student’s t test or
ANOVA and Tukey’s multiple comparison post hoc test.
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Pax8/ and Hyt/Hyt Mice Both Have Impaired
Chondrocyte Differentiation, Reduced Cortical
Bone, and Impaired T3 Target Gene Expression in
Osteoblasts
Pax8/ and hyt/hyt mice had wider growth plates
and immature secondary ossification centers (Fig. 2,
A and B). The extent of the reserve zone (RZ), pro-
liferative zone (PZ), and hypertrophic zone (HZ) in
the growth plate was determined by collagen II and
X in situ hybridization as described (15). The in-
creased growth plate width resulted from widening
of all zones in Pax8/ mice but only of the RZ and
PZ in hyt/hyt mice. Strikingly, the proximal tibia
epiphysis exhibited delayed and incomplete ossifi-
cation in Pax8/ and hyt/hyt mice and was accom-
panied by disrupted growth plate architecture in
both mutant strains. Treatment of Pax8/ mice
with T3/4 between P8 and P13 ameliorated these
abnormalities (Fig. 2A). Growth plate measurements
in HET mice were similar to WT. Mid-diaphysis cor-
tical bone thickness was determined in midline sag-
ittal sections (Fig. 2, D and E) and was reduced by
23% in Pax8/ (P 0.05; n 3) and 26% in hyt/hyt
(P  0.001; n  3) mice. These reductions did not
merely reflect the proportional change associated
with decreased bone length because the ratio of
femur length to cortical bone width was increased
by 35% in Pax8/ (P  0.001) and 50% in hyt/hyt
(P  0.05) mice. Furthermore, the ratio of the diam-
eter between endosteal cortical bone surfaces to the
diameter between periosteal surfaces was in-
creased in both strains. Together with these obser-
vations, expression of the T3 target gene Fgfr1 (16,
17) was markedly reduced in osteoblasts in both
Pax8/ and hyt/hyt mice compared with WT, T3/4-
treated Pax8/ mice, and HET littermates (Fig. 3).
Furthermore, T3/4 treatment of Pax8
/ mice be-
tween P8 and P13 normalized the skeletal pheno-
type, whereas cortical bone measurements also did
not differ between HET and WT mice. Thus, Pax8/
and hyt/hyt mice both have similar defects of endo-
chondral ossification and cortical bone deposition
together with a similar impairment of T3 target gene
expression in osteoblasts.
Fig. 2. Histological Analysis of Ossification in Pax8/ and Hyt/Hyt Mice
A and B, Proximal tibia sections stained with alcian blue/van Gieson from P70 Pax8/ and T3/4-treated (between P8 and P13)
Pax8/mice (A) and P49 hyt/hyt, HET, and WT littermates (B). C, Widths of growth plate zones (RZ, PZ, and HZ) and total growth
plate (RZPZHZ) from P70 WT, T3/4-treated Pax8
/, and Pax8/ or P49 WT, HET, and hyt/hyt mice. D and E, Mid-diaphysis
femurs are shown in P70 WT, T3/4-treated Pax8
/ and Pax8/ mice (D) or P49 WT, HET, and hyt/hyt mice (E). Graphs show
cortical thickness, length/cortical thickness, and endosteal/periosteal diameter ratios in P70 WT, T3/4-treated Pax8
/, and
Pax8/ (D) and P49 WT, HET, and hyt/hyt mice (E). E, Epiphysis; GP, growth plate; IE, immature epiphysis. *, P  0.05; **, P 
0.01; ***, P  0.001 mutant vs. WT; n 3–7; ANOVA and Tukey’s post hoc test. Scale bars, 200 m.
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Pax8/ and Hyt/Hyt Mice Both Have Impaired
Trabecular Remodeling and Reduced
Bone Mineralization
Bone microarchitecture was characterized by topo-
graphical backscattered electron scanning electron
microscopy (BSE-SEM). Pax8/ and hyt/hyt long
bones had reduced cortical thickness and abnormal
trabecular architecture (Fig. 4). In Pax8/ and hyt/
hyt mice, trabeculae were coarser, more plate-like,
and of increased connectivity. Even transient thyroid
hormone treatment of Pax8/ mice improved the
trabecular abnormalities (Fig. 4, A and B), and HET
mice displayed a similar phenotype to WT (Fig. 4, C
and D). Bone mineralization was determined in
Pax8/ proximal humerus and hyt/hyt caudal ver-
tebrae by quantitative compositional BSE-SEM
(qBSE-SEM) (Fig. 5, A and D). The relative and cu-
mulative frequencies of micromineralization densi-
ties were markedly reduced in both Pax8/ (Kol-
mogorov-Smirnov test; D statistic 17.2; P  0.001)
and hyt/hyt (D statistic 16.2; P  0.001) mice (Fig. 5,
B and E). Mineralization in HET mice was similar to
hyt/hyt, which reflects the additional presence of
abnormally retained and highly mineralized calcified
cartilage in hyt/hyt trabeculae. Similarly, Pax8/
bone retained calcified cartilage, consistent with a
trabecular bone remodeling defect in both strains.
T3/4 treatment of Pax8
/ mice between P8 and P13
normalized bone mineralization density and cor-
rected the remodeling defect. Bone volume fraction
(BVF) was reduced by 22% in hyt/hyt mice (P 
Fig. 3. Expression of Fgfr1 in Osteoblasts in Pax8/, T3/4-Treated Pax8
/, and Hyt/Hyt Mice
In situ hybridization of Fgfr1 expression in osteoblasts from P70 Pax8/ and T3/4-treated Pax8
/ mice (A) and P49 hyt/hyt,
HET, and WT littermates (B). Arrows indicate layer of cortical bone lining osteoblasts. CB, Cortical bone. Scale bar, 50 m.
Fig. 4. Topographic Three-Dimensional BSE-SEM Analysis of Bone Structure in Pax8/ and Hyt/Hyt Mice
BSE-SEM views of proximal humerus (A and B) from P70 WT, T3/4-treated (between P8 and P13) Pax8
/, and Pax8/ mice
and proximal tibia (C and D) from P49 WT, HET, and hyt/hyt mice. Scale bars, 200 m.
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0.05) but was indistinguishable between HET and
WT. A similar trend was present in Pax8/ mice in
which a 17% reduction was observed (Fig. 5, C and
F), and this was normalized by T3/4 between P8 and
P13. Femoral bone mineral density (BMD) was also
reduced by 18% in hyt/hyt mice (P  0.05), and a
similar trend was evident in Pax8/ mice in which
a 6% reduction was seen (Fig. 5, C and F). Thus,
Pax8/ and hyt/hyt mice both have impaired tra-
becular bone remodeling and decreased bone
mineralization.
Osteoblasts Express TSHR, but TSH Fails to
Induce cAMP or Alter Differentiation and
Function
Primary osteoblasts cultured for 28 d expressed
Runx2 (runt-related transcription factor 2), Twist2
(second homolog of Drosophila twist), SP7 (osterix),
Bglap2 (osteocalcin), and ColIa1 (collagen type I 1
subunit) mRNAs, confirming their mature osteoblast
phenotype. Expression of these osteoblast markers
on d 21 of culture was evident in cells cultured in the
absence and presence of bovine TSH (bTSH) (Fig. 6A).
Differentiating osteoblasts expressed TSHR mRNA but
did not express TSH or -mRNAs (Fig. 6A). Intracellular
cAMP levels were determined on d 14 and 21. Forskolin
induced a strong cAMP response in osteoblasts but no
response was elicited by bTSH, human TSH (hTSH), a
TSHR-stimulating antibody (M22), or a nonstimulating
TSHR antibody (3G4) (18–20) (Fig. 6B). By contrast, the
stimulating ligands each increased cAMP in FRTL-5 thy-
roid follicular cells (bTSH, P 0.01; hTSH P 0.05; M22
P  0.05; n 2 experiments performed in duplicate),
whereas the nonstimulating 3G4 antibody failed to elicit
a response (Fig. 7B). Consistent with these findings, al-
kaline phosphatase activity and osteocalcin mRNA ex-
pression were unaffected by treatment with TSH
throughout the 28-d period of osteoblast culture (Fig. 6,
C and D). Furthermore, osteoblast function, as deter-
mined by alizarin red staining of mineralized nodules,
was unaffected by TSH (Fig. 6E). Thus, osteoblasts ex-
press TSHR mRNA, but their differentiation and function
are not affected by TSH.
Fig. 5. qBSE-SEM Compositional Analysis of Mineralization Densities and BVF in Pax8/ and Hyt/Hyt Mice
Mineralization densities in proximal humerus (A) from P70 WT, T3/4-treated (between P8 and P13) Pax8
/, and Pax8/ mice
and caudal vertebrae (D) from P49 WT, HET, and hyt/hyt mice. Gray-scale images were pseudocolored with low mineralization
density in blue and high density in gray. Arrows indicate highly mineralized calcified cartilage. Scale bars, 200 m. B and E,
Relative and cumulative frequencies of mineralization densities. **, P  0.01; ***, P  0.001 mutant vs. WT; n  2–4;
Kolmogorov-Smirnov test. C and F, BMD, determined by dual-energy x-ray absorptiometry, and BVF, determined by BSE-SEM,
in P70 WT, T3/4-treated Pax8
/, and Pax8/ mice (C) and P49 WT, HET, and hyt/hyt mice (F). #, P  0.05 for BMD or BVF in
mutant vs. WT; n  2–5 per group; ANOVA followed by Tukey’s multiple comparison post hoc test.
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Osteoclasts Express TSHR, but TSH Fails to Induce
cAMP or Alter Differentiation and Function
Osteoclasts differentiated for 9 d with macrophage
colony-stimulating factor (M-CSF) and receptor acti-
vator of nuclear factor-B ligand (RANKL) with or with-
out bTSH expressed Acp5 [tartrate-resistant acid
phosphatase (TRAP)], Calcr (calcitonin receptor), Ctsk
(cathepsin K), and Tnfrsf11a (receptor activator of nu-
clear factor-B) mRNAs, confirming their osteoclast
phenotype (Fig. 7A). Differentiating osteoclasts ex-
Fig. 6. Primary Calvarial Osteoblast Cultures
A, Southern blot RT-PCR of TSH, TSH, and TSHR mR-
NAs on d 7, 14, 21, and 28 of culture with or without bTSH (10
U/liter) and expression of Runx2, Osterix, Twist2, Osteocal-
cin, and ColIa1mRNAs on d 21. B, cAMP response (SEM) to
1) medium alone, 2) forskolin (10 mol), 3) bTSH (10 U/liter),
4) bTSH (100 U/liter), 5) hTSH (10 U/liter), 6) hTSH (100
U/liter), 7) 3G4 nonstimulating TSHR antibody, and 8) M22
TSHR-stimulating antibody. C, Alkaline phosphatase activity
(SEM). D, Representative Northern blot analysis of osteocal-
cin (OC) mRNA expression on d 7, 14, 21, and 28 of culture
with or without bTSH (10 U/liter) and graph showing mean
osteocalcin mRNA levels from three independent experi-
ments normalized to expression of 18S rRNA. E, Alizarin red
staining.
Fig. 7. Osteoclast Cultures
A, Southern blot RT-PCR of TSH, TSH, and TSHR
mRNAs on d 6, 9, and 12 of culture with or without bTSH (10
U/liter) and expression of Trap, Calcr, Ctsk, and RankmRNAs
on d 9. B, cAMP response (SEM) to 1) medium alone, 2)
forskolin (10 mol), 3) bTSH (10 U/liter), 4) bTSH (100 U/liter),
5) hTSH (10 U/liter), 6) hTSH (100 U/liter), 7) 3G4 nonstimu-
lating TSHR antibody, and 8) M22 TSHR-stimulating antibody
in osteoclasts and thyroid follicular FRTL-5 cells. C, Cell
number (SEM), morphology, and TRAP activity (SEM) on d
9. D, Toluidine blue- and TRAP-stained osteoclasts cultured
on dentine slices for 9 d. Graph shows the fraction of
resorbed surface (SEM) determined by BSE-SEM. E, Re-
sorption pits formed by bone marrow osteoclasts cultured for
12 h. Scale bars, 200 m.
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pressed TSHR mRNA but did not express TSH or -
mRNAs (Fig. 7A). Intracellular cAMP levels were de-
termined on d 9 (Fig. 7B). Forskolin induced a strong
cAMP response but, as in osteoblasts, no response
was elicited after treatment with bTSH, hTSH, or the
M22 TSHR-stimulating antibody. Osteoclast numbers,
morphology, and TRAP activity, a marker of osteoclast
differentiation, did not differ in the absence or pres-
ence of TSH (Fig. 7C). Osteoclasts were also differen-
tiated on dentine slices over a 9-d period, after which
the area of resorbed dentine surface was determined
by topographical BSE-SEM. The total osteoclast pit
resorption surface area was unaffected by TSH (Fig.
7D). Furthermore, the size and number of resorption
pits formed over a 12-h period by osteoclasts ex-
tracted directly from bone and not exposed to M-CSF
and RANKL was not affected by TSH (Fig. 7E). Thus,
osteoclasts express TSHR mRNA, but their differenti-
ation and activity are not affected by TSH.
TSHR Protein Is Expressed at Low Levels in
Osteoblasts and Osteoclasts
RT-PCR studies demonstrated TSHR mRNA expres-
sion in osteoblasts and osteoclasts, but treatment with
TSH or a TSHR-stimulating antibody elicited no cAMP
response. Thus, we investigated TSHR protein expres-
sion in Western blots by an optimized enhanced
chemiluminescence method. TSHR protein was ex-
pressed at the limit of detection in both osteoblasts
and osteoclasts, whereas TSHR protein was readily
observed in FRTL-5 thyroid follicular cells (Fig. 8).
DISCUSSION
These studies compared two divergent models of con-
genital hypothyroidism in which grossly elevated lev-
els of TSH occurred in the presence of either a normal
(Pax8/) or a nonfunctional (hyt/hyt) TSHR. We rea-
soned these mice must display opposing skeletal phe-
notypes if TSH has a major role in bone, whereas they
would be similar if thyroid hormone actions predomi-
nate. The power of this approach lies with the simple
hypothesis and the extremes of the two mouse mod-
els. We used state-of-the-art structural analysis of
skeletal phenotype and quantitation of bone mineral-
ization to provide an unequivocal answer. Thus, the
finding that Pax8/ and hyt/hyt mice both have de-
layed ossification, reduced cortical bone deposition,
impaired osteoblast T3 target gene expression, a tra-
becular bone remodeling defect, and reduced miner-
alization rather than opposing skeletal phenotypes
demonstrates that the skeletal abnormalities of con-
genital hypothyroidism must be independent of sys-
temic TSH concentrations. This conclusion is sup-
ported by the observation that TSH did not influence
primary osteoblast or osteoclast differentiation and
functional activity in vitro.
Skeletal Responses to Hypothyroidism Are
Independent of Systemic TSH
Because TSH action is maximal in Pax8/ mice
(grossly elevated TSH and a functional TSHR) but ab-
sent in hyt/hyt mice (grossly elevated TSH but a non-
functional TSHR), the similarity of their phenotypes
reflects the detrimental skeletal effects of severe thy-
roid hormone deficiency, as reflected by reduced os-
teoblast Fgfr1 expression in both Pax8/ and hyt/hyt
mice, rather than any effect of TSH in bone. Thus, the
skeletal abnormalities in both Pax8/ and hyt/hyt
mice, which have thyroid gland agenesis and hypopla-
sia, respectively, are characteristic of juvenile hypo-
thyroidism in humans and rodents (10, 11, 15, 21) and
reflect the well-described impairment of chondrocyte,
osteoblast, and osteoclast functions that result from a
lack of thyroid hormones (22–28). This interpretation is
supported further by previous data in TR0/0 mice,
which lack all TR isoforms, and TR1PV/ mice,
which harbor a severe dominant-negative mutation in
TR1. Both strains are euthyroid with normal TSH
levels but display delayed endochondral ossification
and reduced bone mineralization due to impaired T3
action in bone (15, 21). Thus, the skeletal phenotype of
congenital hypothyroidism is independent of systemic
TSH.
Rapid Catch-Up Growth after Thyroid Hormone
Treatment
Juvenile hypothyroidism is an important cause of
growth delay in children. Thyroid hormone replace-
ment results in a rapid increase in growth velocity that
often persists until cessation of growth at puberty (10).
Furthermore, the deficit in predicted final height cor-
relates with the severity and duration of hypothyroid-
ism (10, 11).
Fig. 8. TSHR Protein Expression
Western blot of TSHR expression in lysates from thyroid
follicular FRTL-5 cells and primary osteoblasts (OB) and os-
teoclasts (OC).
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The proposed key role for TSH in bone, which re-
sulted from studies of TSHR/mice (7), conflicts with
the current observations in Pax8/ and hyt/hyt mice.
Importantly, TSHR/ mice have congenital hypothy-
roidism (9) but received thyroid extract only from
weaning at 3 wk of age (7). Critically, however, normal
growth velocity in mice is maximal before this time
point when T4 and T3 levels rise rapidly to reach their
physiological peak at 2 wk of age (12, 15). Thus, the
TSHR/ mice were grossly hypothyroid during this
critical stage of thyroid hormone-dependent skeletal
development, and their reported phenotype may re-
flect the skeletal manifestations of catch-up growth
and accelerated bone development in response to
delayed thyroid hormone replacement.
To investigate the sensitivity of the developing skel-
eton to thyroid hormones before weaning, Pax8/
mice were treated with T3/4 between P8 and P13.
Amelioration of the phenotype by T3/4 treatment dem-
onstrates the critical nature of this period for skeletal
development and its dependence on thyroid hor-
mones. Importantly, T3/4 treatment increased cortical
thickness (Fig. 2D) and mineralization of long bones
(Fig. 5B) compared with untreated Pax8/ mice. This
period of T3/4 treatment can be expected to transiently
lower TSH levels. Even so, the observed increase in
cortical thickness and bone mineralization in response
to T3/4 treatment is again inconsistent with the pro-
posal of Abe et al. (7), which predicts that a fall in TSH
should result in a further reduction in bone mineraliza-
tion. Thus, T3/4 treatment of Pax8
/mice strengthens
the conclusion that the skeletal effects of congenital
hypothyroidism result from a lack of thyroid hormones
and are independent of circulating TSH.
Osteoblast and Osteoclast Differentiation and
Function Are Independent of TSH
Although the in vivo data demonstrate that the skeletal
consequences of congenital hypothyroidism cannot
be mediated by TSH, it was also necessary to inves-
tigate whether TSH could exert paracrine actions in
skeletal cells. TSH or - mRNAs were not expressed
in osteoblasts or osteoclasts at any stage of differen-
tiation, indicating TSH does not have a paracrine role.
Moreover, equivalent levels of alkaline phosphatase
activity, osteocalcin expression, and mineral deposi-
tion observed in osteoblast cultures in the absence or
presence of TSH indicates that TSH does not regulate
osteoblast differentiation and function in vitro. Simi-
larly, the presence of comparable cell numbers, TRAP
activities, and dentine resorption in osteoclast cultures
in the absence or presence of TSH indicates that TSH
does not influence osteoclast differentiation and func-
tion in vitro. To exclude the possibility that high con-
centrations of M-CSF and RANKL masked an effect of
TSH on osteoclast activity, we also examined the re-
sponse of freshly isolated bone marrow osteoclasts to
TSH in the absence of these differentiation factors in
12-h dentine resorption assays. TSH did not affect the
size and number of resorption pits in these experi-
ments. Thus, TSH does not influence the differentia-
tion and function of osteoblasts or osteoclasts in vitro.
Osteoblasts and Osteoclasts Express TSHR but
Do Not Signal via the Canonical cAMP Pathway
Osteoblasts and osteoclasts express low levels of
TSHR protein, but no cAMP response to TSH or a
TSHR-stimulating antibody was evident despite de-
tectable basal levels of intracellular cAMP and a robust
response to forskolin in both cell types. This paradox
suggests that the very low levels of TSHR in skeletal
cells elicit negligible cAMP responses or that the ca-
nonical cAMP pathway is not involved in TSH signaling
in bone. Although cAMP is recognized as the major
secondmessenger in thyroid follicular cells, alternative
pathways have been implicated in both thyroid and
extrathyroidal tissues (8, 29, 30). In thyroid follicular
cells, the TSHR associates with various G proteins
(31), and TSH activation of alternative pathways has
been reported; these include phospholipase C (PLC)/
protein kinase C (PKC) (8, 32), Janus kinase (JAK)/
signal transducers and activators of transcription
(STAT3) (33, 34), and phosphatidylinositol 3-kinase
(PI3K)/ribosomal S6 kinase 1 (35). It remains possible
that these noncanonical pathways could mediate ac-
tions of TSH in skeletal cells. Nevertheless, the simi-
larity of the phenotypes in Pax8/ and hyt/hyt mice,
and the lack a demonstrable effect of TSH in vitro,
suggest that any actions of TSH in bone are likely to be
minor in comparison with the effects of T3.
In summary, these studies demonstrate that the
skeletal abnormalities of congenital hypothyroidism
result from thyroid hormone deficiency and are inde-
pendent of systemic TSH.
MATERIALS AND METHODS
Pax8/ and Hyt/Hyt Mice
Pax8/ mice were housed in a certified animal facility ac-
cording to procedures approved by l’Ecole Normale Su-
pe´rieure de Lyon local animal care and use committee.
Pax8/ and WT littermates were derived from heterozygote
crosses to overcome confounding influences of a maternal
homozygote genotype and were analyzed at P14 and P70.
Untreated Pax8/ mice survived spontaneously (36), but to
determine the effect of thyroid hormones before weaning,
some Pax8/ mice received a daily ip injection of T4 (10 g)
and T3 (1 g) between P8 and P13. Hyt/hyt mice were ob-
tained from the Jackson Laboratories (Bar Harbor, ME), and
hyt/hyt, HET, and WT littermates were derived from heterozy-
gous crosses and analyzed at P49.
Biochemical Measurements
Total T4 was measured in P49 WT, hyt/, and hyt/hyt litter-
mate mice by coated-tube RIA adapted for mouse serum
(Diagnostic Products Corp., Los Angeles, CA), and TSH was
determined by a sensitive, heterologous, disequilibrium, dou-
ble-antibody precipitation RIA, as described (37, 38).
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Skeletal Preparations
Limbs from P14 and P70 Pax8/ and P49 hyt/hyt mice and
their littermates were stained with alizarin red and alcian blue
(15, 39). Skeletal preparations were photographed using a
Leica MZ75 binocular microscope (Leica AG, Heerbrugg,
Switzerland), Leica DFC320 digital camera, Leica IM50 Digital
Image Manager, and Leica Twain Module DFC320 image
acquisition software. After linear calibration, tibia and ulna
lengths were determined using ImageJ version 1.33u soft-
ware (http://rsb.info.nih.gov/ij/).
Histology
Limbs were fixed for 48 h in 10% neutral buffered formalin
and decalcified in 10% formic acid and 10% neutral buffered
formalin. P14 limbs were decalcified for 3 d, whereas P49 and
P70 limbs were decalcified for 7 d. Decalcified bones were
embedded in paraffin and 3-m sections stained with van
Gieson and alcian blue 8GX and photographed using a Leica
DM LB2 microscope and DFC320 digital camera. The ex-
pression of collagen II and collagen X mRNA was analyzed in
growth plate sections by in situ hybridization and used to
identify proliferative and hypertrophic zones in growth plate
sections as described (15, 17, 39, 40). Mean values for widths
of the RZ, PZ, HZ, and total growth plate were calculated
from measurements taken at four positions across the prox-
imal tibia using ImageJ. Mean cortical bone dimensions were
calculated from measurements taken at 10 separate posi-
tions along the mid-diaphysis of long bones. In all cases, data
from at least two different levels of sectioning were compared
to ensure consistency of data.
In Situ Hybridization
Fgfr1mRNA expression was analyzed by in situ hybridization
as described (15, 17, 40, 41). Studies were performed in
duplicate on sections obtained from at least three mice per
genotype and repeated three times. Experimental conditions
were optimized separately for comparison of Pax8/, T3/4-
treated Pax8/, and WT littermates and comparison of hyt/
hyt, HET, and WT littermates.
BSE-SEM
Analysis of bone microarchitecture was determined by BSE-
SEM. For topographical three-dimensional imaging, dis-
sected bones were fixed in 70% ethanol and opened longi-
tudinally by removing half the cortical bone and medullary
trabecular elements with a fine tungsten carbide milling tool.
Samples were cleaned of cell remnants by maceration with
an alkaline bacterial pronase, washed, dried, and coated with
carbon and imaged using backscattered electrons, generally
at 30-kV beam potential.
The distribution of mineralization densities within calcified
tissues was quantified by digital image analysis of composi-
tional BSE images at the cubic micrometer volume resolution
scale. Bones were fixed in 10% neutral buffered formalin and
embedded in polymethylmethacrylate. Block faces were cut
through the specimens, which were then polished, coated
with carbon, and analyzed using backscattered electrons in a
Zeiss DSM962 digital scanning electron microscope,
equipped with an annular solid-state BSE detector (KE Elec-
tronics, Toft, Cambridgeshire, UK), operated at 20 kV and 0.5
nA. The mineralization densities of the calcified tissues were
determined by comparison with halogenated dimethacrylate
standards, C22H25O10Br [mean BSE coefficient according to
the procedure of Lloyd (42)  0.1159] to C22H25O10I (mean
BSE coefficient 0.1519). Increasing gradations of micromin-
eralization density were represented in eight equal intervals
by a pseudocolor scheme for presentation of digital images
(43, 44).
BMD was also determined using a PIXImus dual-energy
x-ray absorptiometry mouse densitometer according to the
manufacturer’s instructions (Faxitron, Wheeling, IL).
Cell Culture
Primary osteoblasts were prepared from P2 neonatal CD1
mice. Calvariae were washed in PBS containing penicillin
(100 U/ml), streptomycin (100 g/ml), and amphotericin B
(1.5 g/ml) and diced. Bone fragments were digested twice
with trypsin (0.5%) in EDTA-PBS for 10 min at 37 C and then
five times in collagenase II (0.2%) in Hanks’ balanced salt
solution (Invitrogen, Paisley, UK) for 30 min at 37 C. The final
three digests were pooled and cells resuspended in -MEM
containing 10% heat-inactivated fetal bovine serum (HI-FBS)
and antibiotics. Cells were replated at a density of 5  103
cell/ml in medium containing ascorbic acid (50 g/ml) and
-glycerophosphate (5 mM) with or without bTSH (10 U/liter).
Alkaline phosphatase activity was determined on d 7, 14, 21,
and 28 of culture. Cells were washed in ice-cold PBS and
lysed in Triton X-100/PBS (0.1%). After addition of p-nitro-
phenylphosphate substrate (200l) (Sigma-Aldrich, Stein-
heim, Germany), alkaline phosphatase activity was measured
at 405 nm using Softmax Pro software in a Spectramax
340PC spectrophotometer. Mineralization was determined
by alizarin red staining on d 7, 14, 21, and 28. Cells were
washed in PBS, fixed in 70% ethanol, rehydrated, and
stained for 5 min (45). Digital images were obtained using a
Leica MZ75 microscope and DFC320 camera.
Osteoclast progenitors were prepared from P70 CD1mice.
Bone marrow was flushed from long bones and filtered
through a 70-m mesh (Becton Dickinson UK, Oxford, UK).
Cells were resuspended in -MEM containing HI-FBS (10%),
antibiotics and M-CSF (25 ng/ml) (R&D Systems, Abingdon,
UK), plated at a density of 1.5  106 cells/ml and cultured
overnight. Nonadherent cells were removed and cultured at a
density of 1  106 cells/ml in the presence of M-CSF (25
ng/ml) and RANKL (10 ng/ml) (R&D Systems) with or without
bTSH (10 U/liter). Osteoclast numbers were determined on d
9 of culture. Adherent cells were stained for TRAP expression
using Sigma kit 386A according to the manufacturer’s in-
structions. Digital images were obtained using an Olympus
CKX31 microscope and C3030 digital camera. Cell numbers
were determined by two independent observers, and mature
osteoclasts were defined as TRAP-positive cells, greater than
70 m in size, and containing three or more nuclei (46).
Osteoclast TRAP activity was also determined on d 9. Cells
were washed in PBS and lysed with 0.1% Triton X-100/PBS,
and TRAP activity was determined using a Sigma CS0740 kit
according to the manufacturer’s instructions.
Dentine Resorption Assay
Nonadherent bone marrow cells were seeded at a density of
1  106 cells/ml onto dentine slices (ImmunoDiagnostic Sys-
tems Ltd., Boldon, UK) and cultured in -MEM containing
HI-FBS (10%), antibiotics, M-CSF (25 ng/ml), and RANKL (10
ng/ml) with or without bTSH (10 U/liter). Osteoclasts were
visualized on d 9 after staining with toluidine blue or TRAP
(Sigma kit 386A). Dentine slices were sonicated, dried, car-
bon coated, and imaged by topographic BSE-SEM. The area
of dentine surface resorbed was quantified using ImageJ.
Direct dentine resorption assays were performed using fresh
osteoclasts prepared from long bones of neonatal P3 CD1
mice (47). Bones were diced in -MEM containing HI-FBS
(10%), and a 60-l cell suspension was seeded onto each
dentine slice. After 1 h incubation, nonadherent cells were
removed, and 1 ml -MEM containing HI-FBS with or without
bTSH (10 U/liter) was added. Cells were cultured for another
11 h at 37 C in 5% CO2.
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RT-PCR Analysis
RNA was isolated from primary osteoblasts on d 7, 14, 21,
and 28 and osteoclasts on d 3, 6, and 9. cDNA was synthe-
sized from total RNA (5 g) using the Superscript II First-
Strand Synthesis System (Invitrogen). cDNA (2 l) was used
for PCR amplification of osteoblast and osteoclast markers.
Nucleotide positions of primers are given in the 5–3 direc-
tion: Tsha, forward (117–136) and reverse (557–576) (Gen-
Bank accession no. NM_009889); Tshb, forward (281–300)
and reverse (500–519) (NM_009432); Tshr, forward (130–149)
and reverse (400–418) (NM_011648); Runx2, forward (670–
690) and reverse (1031–1051) (NM_009820); Sp7, forward
(162–181) and reverse (453–472) (NM_130458); Twist2, for-
ward (151–168) and reverse (680–698) (NM_007855); Bglap2,
forward (22–41) and reverse (430–450) (NM_001032298);
Col1a1, forward (1247–1268) and reverse (1498–1518)
(X15896); Acp5, forward (123–144) and reverse (861–882)
(NM_007388); Calcr, forward (883–903) and reverse (1749–
1769) (NM_007588); Ctsk, forward (54–74) and reverse (639–
663) (NM_007802); Tnfrsf11a, forward (143–162) and reverse
(383–402) (NM_009399); and 18s rRNA, forward (2376–2395)
and reverse (2507–2526) (X00686). PCR included an initial
denaturation step at 94 C for 2 min followed by 30–40 cycles
of 30 sec at 94 C, 30 sec at an annealing temperature ranging
between 55 and 62 C depending on the primer pair, and 30
sec elongation at 68 C, followed by a final elongation step at
68 C for 2 min. To ensure specificity of the Tsha, Tshb, and
Tshr RT-PCR products, Southern analysis was performed
using internal oligonucleotide probes.
TSHR Antibodies
A human TSHR-stimulating monoclonal antibody (M22:
IgG1,) (20, 48) was used to stimulate primary osteoblasts
and osteoclasts. A mouse TSHR antibody (3G4:IgG2b,) rec-
ognizing a linear TSHR epitope, is devoid of stimulating ac-
tivity and served as a negative control (18, 19). In all studies,
M22 and 3G4 were used at dilutions of 1:1000 and 1:20,
respectively.
Determination of cAMP Activity
cAMP activity was determined in osteoblasts and osteoclasts
as described (49). Cells were washed and incubated in
Krebs-Ringer-HEPES (KRH) buffer (124 mM NaCl; 5 mM KCl;
1.25 mM MgSO4; 1.45 mM CaCl2; 8 mM glucose; 0.5 g/liter
BSA; 25 mM HEPES buffer, pH 7.6) for 30 min at 37 C. Cells
were incubated in KRH containing rolipram (25 M) (Sigma-
Aldrich) for 60 min at 37 C with addition of forskolin (10 M)
(Sigma-Aldrich,), bTSH (10 or 100 U/liter), hTSH (10 or 100
U/liter), or TSHR antibody M22 or 3G4. In studies with M22,
KRH was replaced with Hanks’ buffered medium (400 mg/
liter KCl, 60 mg/liter KH2PO4, 350 mg/liter NaHCO3, 1000
mg/liter D-glucose, 20 mM HEPES, 222 mM sucrose, 15 g/liter
BSA, 0.5 mM xanthine). After stimulation, cells were treated
with 0.1 M HCl for 5 min, dried under vacuum, and stored at
80 C. The samples were suspended in 500 l and assayed
as described (49). The detection limit of the assay is 0.5
nM/liter.
Western Blotting
Whole-cell lysates were prepared from primary osteoblasts
on d 14 and osteoclasts on d 9. Cells were washed in ice-cold
PBS, lysed in 50 mM Tris-HCl (pH 7.4), 150 mM NaCl2, 2 mM
EDTA, 1% Triton X-100, 0.1% SDS, 1 mM phenylmethylsul-
fonyl fluoride, and 1 g/ml each of aprotinin, leupeptin, and
pepstatin, and sonicated. Samples were centrifuged at
10,000 rpm for 10 min and supernatant proteins separated on
a 4% stacking and 10% resolving polyacrylamide gel before
transfer to a nitrocellulose membrane. Membranes were in-
cubated in nonfat dried milk (20%) in Tween-PBS (0.1%) at
25 C for 2 h, followed by incubation in nonfat dried milk (5%)
in Tween-PBS (0.1%) containing 3G4 (1:50) at 4 C for 16 h.
Antibody 3G4 recognizes a linear epitope common to mouse
and rat TSHR (19). Membranes were washed in Tween-PBS
(0.1%) and incubated with goat antimouse horseradish per-
oxidase 1:80,000 (Pierce UK, Cramlington, UK) for 1 h at 25
C before washing in Tween-PBS (0.1%). TSHR protein was
detected by enhanced chemiluminescence (ECL system;
Pierce UK).
Statistics
Normally distributed data were analyzed by Student’s t test
or ANOVA followed by Tukey’s multiple comparison post hoc
test. P  0.05 was considered significant. Frequency distri-
butions of mineralization densities were compared using the
Kolmogorov-Smirnov test, in which P values for the D statis-
tic in 1024 pixel data sets were D 6.01, P 0.05; D 7.20,
P  0.01; and D  8.62, P  0.001.
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